Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Innogenetics grants GlaxoSmithKline Biologicals a license for use of HPV SPF10 genotyping technology in clinical studies on HPV

03 Jul 2008 - Innogenetics announced that it has granted GlaxoSmithKline Biologicals (GSK) a worldwide non-exclusive restricted license to use its proprietary SPF10 technology in clinical and epidemiological human papillomavirus (HPV) vaccine studies. Innogenetics will receive royalties for each individual test performed during the studies.
 
Cervical cancer is caused by persistent infection with HPV, and is the second most common cancer among women worldwide, with some 500,000 new cases and 250,000 deaths due to this disease each year. In Europe, there are approximately 50,000 new cases and 25,000 cervical cancer deaths reported annually, while in the US more than 11,000 new cases and 3,800 deaths are expected in 2008.
 
GSK has licensed Innogenetics' SPF10 primer technology in order to continue its current and future clinical and epidemiological studies in the context of further development of some of their prophylactic vaccines directed against HPV.